申请人:Laroche-Navarron, S.A.
公开号:US04400381A1
公开(公告)日:1983-08-23
New compounds of the formula ##STR1## and the pharmaceutically acceptable acid addition salts thereof, wherein M is selected from the group consisting of hydrogen, morpholino, benzylamino, di-n-lower alkylamine, n-lower alkylamine, and aryl piperazino; Z.sub.1 and Z.sub.2 are each independently selected from the group consisting of CH.sub.2, CHOB and C.dbd.O, wherein B is selected from the group consisting of hydrogen and alkanoyl; Y is oxygen or sulfur; n is an integer from 0-4 but cannot be zero when Z.sub.1 is CHOB; m is an integer from 0-4 but cannot be zero when Z.sub.2 is CHOB, or when m is hydrogen; R.sub.1, R.sub.2 and R.sub.3 are each independently hydrogen, halogen, hydroxy, trifluoromethyl, alkyl or alkoxy; and R.sub.4 and R.sub.5 are each independently lower alkyl, with the proviso that both R.sub.4 and R.sub.5 cannot be methyl when M is hydrogen; are antihistamines and are therefore useful in the treatment of respiratory diseases including asthma, hay fever, allergies and the common cold. They are also vasodilators.
新化合物的化学式为##STR1##及其药学上可接受的酸盐,其中M选自氢、吗啡啶基、苄氨基、二个n-较低烷胺基、n-较低烷胺基和芳基哌嗪基; Z.sub.1和Z.sub.2分别选自CH.sub.2、CHOB和C.dbd.O,其中B选自氢和烷酰基; Y为氧或硫; n为0-4的整数,但当Z.sub.1为CHOB时不能为零; m为0-4的整数,但当Z.sub.2为CHOB或m为氢时不能为零; R.sub.1、R.sub.2和R.sub.3分别为氢、卤素、羟基、三氟甲基、烷基或烷氧基; R.sub.4和R.sub.5分别为较低烷基,但当M为氢时R.sub.4和R.sub.5不能同时为甲基; 这些化合物是抗组胺剂,因此在治疗包括哮喘、花粉热、过敏和普通感冒在内的呼吸道疾病中有用。它们也是血管扩张剂。